Brief: Delcath Systems Inc Expects To Submit NDA To FDA During Q1 2023 For Hepzato Kit
10/01/2023 21:24
Jan 10 (Reuters) - Delcath Systems Inc DCTH.O :
* DELCATH SYSTEMS INC - NOW EXPECTS TO SUBMIT NDA TO U.S.
FDA
DURING Q1 2023 FOR ITS HEPZATO KIT
Source: (shorturl.at/lFLNX)
Further company coverage: DCTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Delcath Systems Q1 revenue beats on Hepzato growth
Brief: Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology
Delcath Q4 revenue rises 37%, beats estimates
Brief: Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)